Drugs / CDX-3379
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT02473731 | Oct 2015 → Sep 2016 | head and neck squamous cell carcinoma | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02456701 | Jun 2015 → Oct 2016 | thyroid cancer | Celldex Therapeutics | Completed | Met primary |
| Phase 1 | NCT02014909 | Jan 2014 → May 2017 | cancer of unknown primary site | Celldex Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03580382 | Jul → Sep 2018 | melanoma | NYU Langone Health | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03254927 | Mar 2018 → Sep 2020 | head and neck squamous cell carcinoma | Celldex Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDX-3379 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03580382 ↗ |
| Known as | KTN3379 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02456701 ↗ |
| Known as | MEDI-3379 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650292 ↗ |
| Action | Inhibit | “This study demonstrates that CDX-3379 can inhibit tumor ErbB3 phosphorylation in HNSCC.” PMID 31308059 ↗ Jul 2019 |
| Modality | Monoclonal antibody | “CDX-3379 is a fully human monoclonal antibody” NCT03254927 ↗ |
| Route | Intravenous | “15mg/kg IV Q3W” NCT03580382 ↗ |
| Target | ERBB3 | “CDX-3379 is a fully human monoclonal antibody that binds to a molecule called human epidermal growth factor receptor 3 (HER3 or ErbB3)” NCT03254927 ↗ |